Narcotic Avoidance After Robotic Radical Cystectomy Allows Routine of Only Two-Day Hospital Stay.

OBJECTIVE: To evaluate the outcomes of a narcotic-sparing clinical pathway after robotic-assisted radical cystectomy (RARC) with ileal conduit targeting discharge on postoperative day #2 and report postoperative narcotic consumption, pain scores, and the resulting length of stay (LOS). METHODS: We reviewed a single-surgeon series of consecutive RARCs between August 2015 and September 2020. Acetaminophen and ketorolac were given with thorough patient education reserving oral narcotics for breakthrough pain. Intravenous narcotics were intentionally excluded from postoperative orders. Alvimopan was given once it became available. Subcutaneous ropivacaine pain pumps were removed before discharge. Discharge criteria included diet, oral analgesia, ambulation, and bowel function. Narcotic use and pain scores were evaluated to deternine the success of the applied narcotic-avoidance strategy. RESULTS: None of the 54 patients required intravenous narcotics postoperatively, and 19 patients (35%) never required even oral narcotics. Mean pain scores were higher in patients who required oral narcotics (4.3/11 vs 3.0/11, P = .001, respectively). Among 35 patients who received narcotics, mean tablets taken were 4.3/d (range, 1-13) with 68% using 8 or less tablets during their entire LOS. Mean LOS was 2.1 d (range 1-4). Five patients (9%) were discharged on POD#1, 37/54 (68.5%) on POD #2, 10/54 (18.5%) on POD#3 and 2/54 (4%) on POD #4. Eight patients (15%) were readmitted within 90 days. CONCLUSION: Minimizing narcotics after RARC with conduit allowed for a 2-day LOS in the majority of patients and the shortest ever reported mean LOS after cystectomy, essentially halving hospitalization time. Patient education is critical to minimizing narcotic usage.

Impact of the COVID-19 Crisis on Same-day Discharge After Robotic Urologic Surgery.

OBJECTIVE: To assess the impact of the COVID-19 pandemic on the rate of same-day discharge (SDD) after robotic surgery METHODS: We reviewed our robotic surgeries during COVID-19 restrictions on surgery in Ohio between March 17 and June 5, 2020 and compared them with robotic procedures before COVID-19 and after restrictions were lifted. We followed our formerly described protocol in use since 2016 offering the option of SDD to all robotic urologic surgery patients, regardless of procedure type or patient-specific factors. RESULTS: During COVID-19 restrictions (COV), 89 robotic surgeries were performed and compared with 1667 of the same procedures performed previously (pre-COV) and 42 during the following month (post-COV). Among COV patients 98% (87/89 patients) opted for same-day discharge after surgery versus 52% in the historical pre-COV group (P < .00001). Post-COV, the higher rate of SDD was maintained at 98% (41/42 patients). There were no differences in 30-day complications or readmissions between SDD and overnight patients with only 2 COV (2%) and no post-COV 30-day readmissions. CONCLUSION: SDD after robotic surgery was safely applied during the COVID-19 crisis without increasing complications or readmissions. SDD may allow continuation of robotic surgery despite limited hospital beds and when minimizing hospital stay is important to protect postoperative patients from infection. Our experience suggests that patient attitude is a major factor in SDD after robotic surgery since the proportion of patients opting for SDD was much higher during COV and continued post-COV. Consideration of SDD long-term may be warranted for cost savings even in the absence of a crisis.

Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

Patients with interstitial cystitis/bladder pain syndrome (IC/BPS) can potentially develop symptom flares after exposure to minor bladder irritants such as subclinical bacterial infection. To reproduce this symptom onset, we intravesically instilled a sub-noxious dose of uropathogenic E. coli component lipopolysaccharide (LPS) in young URO-OVA/OT-I mice, a transgenic autoimmune cystitis model that spontaneously develops bladder inflammation at ≥10 weeks of age. Female URO-OVA/OT-I mice (6-weeks old) were treated intravesically with phosphate-buffered saline (PBS) or PBS containing a sub-noxious dose (1 µg) of LPS. Mice were evaluated for bladder inflammation, pelvic pain, and voiding dysfunction at days 1, 7, and 14 post-treatment. Mice treated with LPS but not PBS developed early bladder inflammation with increased macrophage infiltration. Accordingly, the inflamed bladders expressed increased levels of mRNA for proinflammatory cytokines (IL-1ß and IL-6) and pain mediator (substance P precursor). In addition, LPS-treated mice exhibited pelvic pain and voiding dysfunction such as increased urinary frequency and reduced bladder capacity. These functional changes sustained up to day 14 tested. Our results indicate that a single sub-noxious dose of intravesical LPS triggers early bladder inflammation and symptom onset in URO-OVA/OT-I mice, providing a useful model for IC/BPS symptom flare study.

Radiation Exposure During Percutaneous Ablation of Small Renal Masses: A Multi-Institutional Multimodality Analysis.

OBJECTIVE: To understand the effective radiation dose during percutaneous cryoablation (CA) and radiofrequency ablation (RFA) and characterize variables that may affect the individual dose. MATERIALS AND METHODS: The effective radiation dose was determined by conversion of the dose-length product from CT scans performed during percutaneous CA or RFA for patients with solitary renal masses (<4 cm) at four academic centers. Radiation dose per case was compared between patients and institutions using multivariate and univariate analysis. Lifetime attributable risk of cancer was calculated for each institution and utilized to determine the number needed to harm for a range of ages at the time of exposure. RESULTS: One hundred twenty-three patients met the inclusion criteria with a mean age of 71 years. Sixty-nine percent of patients were male, mean body-mass index (BMI) was 29.4, and mean tumor size was 2.2 cm. The mean effective radiation dose per ablation was 40 mSv (range 3.7-147). On multivariate analysis, only BMI and institution were associated with the radiation dose. No significant difference in radiation exposure was seen for RFA or CA procedures. CONCLUSIONS: Radiation exposure during percutaneous ablation is similar to a multiphase CT scan. However, there is wide variability in individual treatment exposure, varying from 3.7 to 147 mSv, depending primarily on institution and BMI. Standardization of protocols is required to achieve as low as reasonably achievable levels of radiation.

Male contraception: history and development.

Although the twentieth century has seen great strides in the development of female contraception, not a single new agent has been introduced as an approved method for common use for male contraception. Condoms (considered uncomfortable by some) and vasectomy (a permanent invasive procedure) are the only options provided to men, leaving an undue burden on women to bear contraceptive responsibility. Significant developments have, however, been made with regard to hormonal and nonhormonal contraception, and minor, reversible, procedural contraception. This article reviews the currently available, soon to be available, and theoretically possible methods of male contraception.

Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion.

Contrast-enhanced ultrasound (CEUS) has demonstrated utility in the monitoring of blood flow in tissues, organs and tumors. However, current CEUS methods typically provide only relative image-derived measurements, rather than quantitative values of blood flow in milliliters/minute per gram of tissue. In this study, CEUS derived parameters of blood flow are compared with absolute measurements of blood flow in rodent kidneys. Additionally, the effects of contrast agent infusion rate and transducer orientation on image-derived perfusion measurements are assessed. Both wash-in curve and time-to-refill algorithms are examined. Data illustrate that for all conditions, image-derived flow measurements were well-correlated with transit-time flow probe measurements (R > 0.9). However, we report differences in the sensitivity to flow across different transducer orientations as well as the contrast analysis algorithm utilized. Results also indicate that there exists a range of contrast agent flow rates for which image-derived estimates are consistent.

Microbubbles in Imaging: Applications Beyond Ultrasound.

Since their introduction as ultrasound contrast agents, microbubbles have demonstrated the potential to revolutionise the use of ultrasound at the bedside. Aside from clinical application, where microbubbles are used to enhance ultrasonic assessment of myocardial perfusion, they have demonstrated potential in an exciting host of pre-clinical ultrasound imaging and therapeutic applications. These include the ability to target specific cellular markers of disease, provide dynamic blood flow estimation, deliver localised chemotherapy, potentiate the mechanisms of gene therapy, enhance lesion ablation through cavitation, and spatiotemporally permeabilise the blood-brain barrier. The unique and flexible construction of microbubbles not only enables a variety of ultrasound applications, but also opens the door to detection of microbubbles with modalities other than ultrasound. In this review, non-ultrasound imaging applications utilizing microbubbles are discussed, including MRI, PET, and DEI. These various imaging approaches illustrate novel applications of microbubbles, and may provide the groundwork for future multi-modality imaging or image-guided therapeutics.

The effects of various additives on setting properties of MTA.

Delayed setting times may limit the use of mineral trioxide aggregate (MTA) in endodontic procedures. The purpose of this study was to identify types and amounts of MTA additives to enhance its setting properties. Additives tested include saline, 2% lidocaine, 3.0% NaOCl gel, chlorhexidine gluconate gel, K-Y Jelly, 3% and 5% CaCl2. The setting times were evaluated using a Vicat apparatus; compressive strengths of set materials were evaluated with an Instron machine. NaOCl gel, K-Y Jelly and 5% CaCl2 decreased the setting time to 20 to 25 min; compressive strengths of these set materials were significantly lower than MTA mixed with water (p < 0.05). Because MTA mixed with NaOCl gel demonstrated good working properties and improved setting time, this combination may be a viable option in single visit procedures where compressive strength of the material is not a critical issue.